Inclusion Criteria:

Patients may be entered in the study only if they meet all of the following criteria:

1. Male or female patient ≥ 18 years of age;

2. Histologically or cytologically confirmed inoperable NSCLC stage III disease;

3. Patient must have received chemo-radiotherapy with a curative intent with the
following definition: any planned regimen consisting of a platinum-doublet containing
chemotherapy given concomitantly with up to 66Gy of radiation therapy. Gemcitabine
cannot be part of the platinum-based doublet;

4. Life expectancy of ≥ 3 months;

5. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 2;

6. Patients must have adequate bone marrow function as evidenced by absolute neutrophil
count (ANC) ≥ 1.0 X 109/L, hemoglobin ≥ 9.0 g/dL (a hemoglobin < 9.0 g/dL at
Screening is acceptable if it is corrected to ≥ 9 g/dL by growth factor or
transfusion prior to first dose), and platelet count ≥ 75 X 109/L (platelet counts
below 75 X 109/L may be re-screened within 4 weeks of chemoradiotherapy);

7. Patients must have adequate liver function as evidenced by bilirubin ≤ 1.5 times the
upper limit of the normal range (ULN), and alkaline phosphatase, alanine
aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 X ULN;

8. Female patients of childbearing potential (i.e. ovulating, premenopausal, not
surgically sterile), and all male patients are required to be sexually abstinent or
use a medically accepted contraceptive regimen during their participation in the
study and for 90 days after study completion. Medically accepted contraceptive
methods are defined as those with 90% or greater efficacy;

9. Females of childbearing potential must have a negative pregnancy test;

10. Females may not be breastfeeding; and

11. Ability to understand and willingness to sign a written informed consent.

Exclusion Criteria:

Patients will not be entered in the study for any of the following reasons:

1. Prior treatment with gemcitabine, prior targeted therapy (including erlotinib
[Tarceva®], or gefitinib [Iressa®]), or immunological therapy including tumor vaccine
therapy intended for the management of NSCLC;

2. A minimum of 1 week and a maximum of 4 weeks must have elapsed from the
chemo-radiotherapy and patient must have recovered from all treatment-related
toxicities to Grade ≤ 1 (CTCAE version 4.03), except for alopecia;

3. History of other malignancies except: (1) adequately treated basal or squamous cell
carcinoma of the skin; (2) curatively treated, a) in situ carcinoma of the uterine
cervix, b) prostate cancer, or c) superficial bladder cancer; or (3) other curatively
treated solid tumor with no evidence of disease for ≥ 3 years;

4. Received treatment in another clinical study within the 30 days prior to commencing
study treatment or patients who have not recovered from side effects of an
investigational drug to Grade ≤ 1 (CTCAE version 4.03), except for alopecia;

5. Are currently receiving any other cancer treatment, even if given with palliative
intent;

6. Uncontrolled pleural effusions, ascites, or other third space fluid collections;

7. Uncontrolled diabetes mellitus Type 1 or 2;

8. Significant cardiovascular impairment (history of congestive heart failure > New York
Heart Association (NYHA) Grade II, unstable angina or myocardial infarction within
the past 6 months, or serious cardiac arrhythmia);

9. Patients with organ allografts requiring immunosuppression;

10. Need for systemic steroid treatment unless chronic daily dose used is ≤ 5mg
prednisone or equivalent. Note: Higher dose systemic steroid treatment (≥ 60mg/day of
prednisone or equivalent) administered for ≤ 2 weeks in any single episode is
permissible if administered for an acute inflammatory condition;

11. Known severe adverse reactions to vaccines;

12. Known severe adverse events or allergy to GM-CSF;

13. Known positive human immunodeficiency virus (HIV), known hepatitis B surface antigen,
or hepatitis C positive; and

14. Have any medical condition that would interfere with the conduct of the study.